Compugen Ltd. (NASDAQ:CGEN) Shares Sold by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC lessened its position in Compugen Ltd. (NASDAQ:CGEN) by 8.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,201,523 shares of the biotechnology company’s stock after selling 112,910 shares during the period. Taylor Frigon Capital Management LLC owned approximately 1.35% of Compugen worth $2,175,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Heron Bay Capital Management purchased a new stake in Compugen in the 1st quarter valued at approximately $32,000. Secure Asset Management LLC purchased a new stake in shares of Compugen in the second quarter valued at approximately $69,000. Squarepoint Ops LLC boosted its stake in shares of Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 16,253 shares in the last quarter. Rothschild Investment LLC acquired a new position in Compugen during the second quarter worth $380,000. Finally, ARK Investment Management LLC raised its position in Compugen by 4.7% in the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after acquiring an additional 48,979 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

Compugen Price Performance

Shares of CGEN stock traded up $0.01 during midday trading on Thursday, reaching $1.70. 49,568 shares of the company traded hands, compared to its average volume of 414,754. The firm has a market cap of $151.26 million, a PE ratio of -8.89 and a beta of 2.64. The firm’s 50 day simple moving average is $1.85 and its two-hundred day simple moving average is $1.91. Compugen Ltd. has a 1-year low of $0.53 and a 1-year high of $3.03.

Compugen (NASDAQ:CGEN) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.06. The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $2.68 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. As a group, research analysts anticipate that Compugen Ltd. will post 0.15 earnings per share for the current fiscal year.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.